Tofacitinib citrate

Overview

Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and is being studied for treatment of psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection. (source: http://en.wikipedia.org/wiki/Tofacitinib).

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Inflammation / Immunology | JAK

Product Information

• Catalog No.: B0084-461917
• CAS No.: 540737-29-9
• Molecular Formula: C22H28N6O8
• Molecular Weight: 504.5
• Purity: 98%
• Storage: Store at 2-8 °C
• Solubility: In Vitro : DMSO : ≥ 122.5 mg/mL (242.82 mM) H2O : 5 mg/mL (9.91 mM; Need ultrasonic and warming)

Source

Original product source